Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary *UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot Campaign in North Carolina
View HTML
Toggle Summary Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016
-- Study Advancing Genomic-Level Understanding of Hürthle Lesions Also Presented --
View HTML
Toggle Summary CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
Greater than 50 Percent Reduction in Patients Classified as Low Risk for Lung Cancer SAN FRANCISCO --(BUSINESS WIRE)-- Correcting quote attribution in the third paragraph of release issued Nov. 1, 2017 . The corrected release reads: VERACYTE ANNOUNCES PRESENTATION OF NEW CLINICAL UTILITY DATA AT
View HTML
Toggle Summary Data Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2016 /PRNewswire/ --  Veracyte, Inc.  ( NASDAQ : VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies
View HTML
Toggle Summary Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"
-- Findings suggest that test's use reduces invasive lung-cancer diagnostic procedures by 28 percent and is cost-effective --
View HTML
Toggle Summary Data from Multiple Studies Evaluating Veracyte's Genomic Classifiers for Lung Cancer and Idiopathic Pulmonary Fibrosis to Be Presented at ATS 2016
SOUTH SAN FRANCISCO, Calif. , May 3, 2016 /PRNewswire/ -- Veracyte, Inc. ( NASDAQ : VCYT) today announced that data from multiple studies supporting the company's genomic tests to resolve ambiguity in pulmonary disease diagnosis will be presented at the American Thoracic Society (ATS) 2016
View HTML
Toggle Summary Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
Additional Data Presented on Development Of Company's Next-Generation Afirma Genomic Sequencing Classifier
View HTML
Toggle Summary Fast Company Names Veracyte CEO, Bonnie Anderson, to Its "100 Most Creative People in Business 2015" List
SOUTH SAN FRANCISCO, Calif. , May 11, 2015 /PRNewswire/ -- Veracyte, Inc . (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, announced that company President and CEO Bonnie H. Anderson has been selected to Fast Company 's " 100 Most Creative People in
View HTML
Toggle Summary Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis
Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis Cambridge, Mass. and South San Francisco, Calif. --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY ), and Veracyte, Inc., a molecular diagnostics company
View HTML